Tyligand Bioscience's Hong Kong IPO Prospectus Expires on July 29 After Six-Month Validity Period

According to Zhitong Caijing, Tyligand Bioscience Ltd.-B's Hong Kong IPO prospectus expired on July 29, 2026, six months after its submission on January 29, 2026. CITIC Securities served as the exclusive sponsor for the offering. The clinical-stage biopharmaceutical company, founded in 2017, focuses on developing innovative oncology therapies.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments